Skip to main content
. Author manuscript; available in PMC: 2015 Jul 31.
Published in final edited form as: Cell. 2014 Jul 31;158(3):564–578. doi: 10.1016/j.cell.2014.05.045

Figure 6. Increased HSF1 activation in the stroma is associated with decreased survival in lung cancer patients.

Figure 6

(A) Lung cancer resections from 5 patients were stained with anti-HSF1 (brown), anti-SMA (brown) or a combination of both antibodies (HSF1 in brown; SMA in red). Representative images are shown. Scale bar = 20μm (B–C) Lung cancer resections from 72 patients with Stage I disease were stained with anti-HSF1 antibodies and scored for HSF1 activation in the stromal cells and in the cancer cells. (B) HSF1 stromal scores are correlated with disease-free survival by KM analysis. (C) KM analysis of disease-free survival for patients with concordant high or low HSF1 scores in both stromal cells and cancer cells. (D) Stromal HSF1 levels in KRAS mutant tumors (n=18) from the lung cancer cohort correlate with disease-free survival by KM analysis. See also Figure S6 and Table S7.